ArticleInternational journal of surgery (London, England)2026
Omitting axillary dissection in breast cancer patients with one to two positive sentinel nodes undergoing mastectomy: a retrospective and prospective cohort study with a target trial emulation.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous trials have demonstrated the safety of omitting axillary lymph node dissection (ALND) in cT1-3, cN0 breast cancer patients with one to two sentinel lymph node (SLN) involvement undergoing breast-conserving surgery (BCS). However, their applicability to mastectomy patients - who do not routinely receive chest wall irradiation - remains unclear. This study aimed to evaluate whether omitting ALND is noninferior to completion of ALND among patients undergoing mastectomy. Methods: We emulated a target multicenter, nonblinded, noninferiority trial to compare sentinel lymph node biopsy only (SLNB only) and SLNB plus ALND using combined prospective and retrospective cohorts. Eligible patients had cT1-3, cN0 breast cancer with one to two SLN metastases. The primary endpoint was 5-year recurrence-free survival (RFS). Noninferiority was defined as a hazard ratio (HR) of less than 1.54 comparing the SLNB-only group to the ALND group. This study was prospectively registered with Chictr.org.cn. Results: Among 1090 included patients, 438 (40.2%) received SLNB only and 652 (59.8%) received ALND. After a median follow-up of 4.74 years, 88 patients experienced recurrence or died. The estimated 5-year RFS was 91.5% (95% CI, 89.1-93.9) in the SLNB only group and 91.8% (95% CI, 88.7-95.1) in the ALND group (HR = 0.83; 95% CI, 0.51-1.33; P Conclusion: Results of this targeted trial revealed that ALND can be omitted in patients undergoing mastectomy with clinically node-negative, cT1-3 invasive breast cancer who had one to two SLN metastases. These findings further inform the de-escalation of axillary surgery in breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.